Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Issue Cover for Volume 29, Number 9—September 2023

Volume 29, Number 9—September 2023

[PDF - 50.53 MB - 240 pages]

Synopses

Medscape CME Activity
Characteristics of Hard Tick Relapsing Fever Caused by Borrelia miyamotoi, United States, 2013–2019 [PDF - 1.14 MB - 11 pages]
D. W. McCormick et al.

Borrelia miyamotoi, transmitted by Ixodes spp. ticks, was recognized as an agent of hard tick relapsing fever in the United States in 2013. Nine state health departments in the Northeast and Midwest have conducted public health surveillance for this emerging condition by using a shared, working surveillance case definition. During 2013–2019, a total of 300 cases were identified through surveillance; 166 (55%) were classified as confirmed and 134 (45%) as possible. Median age of case-patients was 52 years (range 1–86 years); 52% were male. Most cases (70%) occurred during June–September, with a peak in August. Fever and headache were common symptoms; 28% of case-patients reported recurring fevers, 55% had arthralgia, and 16% had a rash. Thirteen percent of patients were hospitalized, and no deaths were reported. Ongoing surveillance will improve understanding of the incidence and clinical severity of this emerging disease.

EID McCormick DW, Brown CM, Bjork J, Cervantes K, Esponda-Morrison B, Garrett J, et al. Characteristics of Hard Tick Relapsing Fever Caused by Borrelia miyamotoi, United States, 2013–2019. Emerg Infect Dis. 2023;29(9):1719-1729. https://doi.org/10.3201/eid2909.221912
AMA McCormick DW, Brown CM, Bjork J, et al. Characteristics of Hard Tick Relapsing Fever Caused by Borrelia miyamotoi, United States, 2013–2019. Emerging Infectious Diseases. 2023;29(9):1719-1729. doi:10.3201/eid2909.221912.
APA McCormick, D. W., Brown, C. M., Bjork, J., Cervantes, K., Esponda-Morrison, B., Garrett, J....Kugeler, K. J. (2023). Characteristics of Hard Tick Relapsing Fever Caused by Borrelia miyamotoi, United States, 2013–2019. Emerging Infectious Diseases, 29(9), 1719-1729. https://doi.org/10.3201/eid2909.221912.

Medscape CME Activity
Foodborne Botulism, Canada, 2006–2021 [PDF - 858 KB - 8 pages]
R. A. Harris et al.

During 2006–2021, Canada had 55 laboratory-confirmed outbreaks of foodborne botulism, involving 67 cases. The mean annual incidence was 0.01 case/100,000 population. Foodborne botulism in Indigenous communities accounted for 46% of all cases, which is down from 85% of all cases during 1990–2005. Among all cases, 52% were caused by botulinum neurotoxin type E, but types A (24%), B (16%), F (3%), and AB (1%) also occurred; 3% were caused by undetermined serotypes. Four outbreaks resulted from commercial products, including a 2006 international outbreak caused by carrot juice. Hospital data indicated that 78% of patients were transferred to special care units and 70% required mechanical ventilation; 7 deaths were reported. Botulinum neurotoxin type A was associated with much longer hospital stays and more time spent in special care than types B or E. Foodborne botulism often is misdiagnosed. Increased clinician awareness can improve diagnosis, which can aid epidemiologic investigations and patient treatment.

EID Harris RA, Tchao C, Prystajecky N, Weedmark K, Tcholakov Y, Lefebvre M, et al. Foodborne Botulism, Canada, 2006–2021. Emerg Infect Dis. 2023;29(9):1730-1737. https://doi.org/10.3201/eid2909.230409
AMA Harris RA, Tchao C, Prystajecky N, et al. Foodborne Botulism, Canada, 2006–2021. Emerging Infectious Diseases. 2023;29(9):1730-1737. doi:10.3201/eid2909.230409.
APA Harris, R. A., Tchao, C., Prystajecky, N., Weedmark, K., Tcholakov, Y., Lefebvre, M....Austin, J. W. (2023). Foodborne Botulism, Canada, 2006–2021. Emerging Infectious Diseases, 29(9), 1730-1737. https://doi.org/10.3201/eid2909.230409.

Participatory Mathematical Modeling Approach for Policymaking during the First Year of the COVID-19 Crisis, Jordan [PDF - 2.55 MB - 9 pages]
S. Bellizzi et al.

We engaged in a participatory modeling approach with health sector stakeholders in Jordan to support government decision-making regarding implementing public health measures to mitigate COVID-19 disease burden. We considered the effect of 4 physical distancing strategies on reducing COVID-19 transmission and mortality in Jordan during March 2020–January 2021: no physical distancing; intermittent physical distancing where all but essential services are closed once a week; intermittent physical distancing where all but essential services are closed twice a week; and a permanent physical distancing intervention. Modeling showed that the fourth strategy would be most effective in reducing cases and deaths; however, this approach was only marginally beneficial to reducing COVID-19 disease compared with an intermittently enforced physical distancing intervention. Scenario-based model influenced policy-making and the evolution of the pandemic in Jordan confirmed the forecasting provided by the modeling exercise and helped confirm the effectiveness of the policy adopted by the government of Jordan.

EID Bellizzi S, Letchford N, Adib K, Probert W, Hancock P, Alsawalha L, et al. Participatory Mathematical Modeling Approach for Policymaking during the First Year of the COVID-19 Crisis, Jordan. Emerg Infect Dis. 2023;29(9):1738-1746. https://doi.org/10.3201/eid2909.221493
AMA Bellizzi S, Letchford N, Adib K, et al. Participatory Mathematical Modeling Approach for Policymaking during the First Year of the COVID-19 Crisis, Jordan. Emerging Infectious Diseases. 2023;29(9):1738-1746. doi:10.3201/eid2909.221493.
APA Bellizzi, S., Letchford, N., Adib, K., Probert, W., Hancock, P., Alsawalha, L....Nabeth, P. (2023). Participatory Mathematical Modeling Approach for Policymaking during the First Year of the COVID-19 Crisis, Jordan. Emerging Infectious Diseases, 29(9), 1738-1746. https://doi.org/10.3201/eid2909.221493.
Research

Compliance Trajectory and Patterns of COVID-19 Preventive Measures, Japan, 2020–2022 [PDF - 1.57 MB - 10 pages]
T. Kusama et al.

COVID-19 remains a global health threat. Compliance with nonpharmaceutical interventions is essential because of limited effectiveness of COVID-19 vaccines, emergence of highly contagious variants, and declining COVID-19 antibody titers over time. We evaluated compliance with 14 nonpharmaceutical intervention–related COVID-19 preventive behaviors, including mask wearing, ventilation, and surface sanitation, in a longitudinal study in Japan using 4 waves of Internet survey data obtained during 2020–2022. Compliance with most preventive behaviors increased or remained stable during the 2-year period, except for surface sanitation and going out behaviors; compliance with ventilation behavior substantially decreased in winter. Compliance patterns identified from latent class analysis showed that the number of persons in the low compliance class decreased, whereas those in the personal hygiene class increased. Our findings reflect the relaxation of mobility restriction policy in Japan, where the COVID-19 pandemic continues. Policymakers should consider behavioral changes caused by new policies to improve COVID-19 prevention strategies.

EID Kusama T, Takeuchi K, Tamada Y, Kiuchi S, Osaka K, Tabuchi T. Compliance Trajectory and Patterns of COVID-19 Preventive Measures, Japan, 2020–2022. Emerg Infect Dis. 2023;29(9):1747-1756. https://doi.org/10.3201/eid2909.221754
AMA Kusama T, Takeuchi K, Tamada Y, et al. Compliance Trajectory and Patterns of COVID-19 Preventive Measures, Japan, 2020–2022. Emerging Infectious Diseases. 2023;29(9):1747-1756. doi:10.3201/eid2909.221754.
APA Kusama, T., Takeuchi, K., Tamada, Y., Kiuchi, S., Osaka, K., & Tabuchi, T. (2023). Compliance Trajectory and Patterns of COVID-19 Preventive Measures, Japan, 2020–2022. Emerging Infectious Diseases, 29(9), 1747-1756. https://doi.org/10.3201/eid2909.221754.

COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020–2021 [PDF - 1.35 MB - 8 pages]
C. J. Atherstone et al.

The SARS-CoV-2 Delta variant, first identified in October 2020, quickly became the dominant variant worldwide. We used publicly available data to explore the relationship between illness and death (peak case rates, death rates, case-fatality rates) and selected predictors (percentage vaccinated, percentage of the population >65 years, population density, testing volume, index of mitigation policies) in 45 high-income countries during the Delta wave using rank-order correlation and ordinal regression. During the Delta-dominant period, most countries reported higher peak case rates (57%) and lower peak case-fatality rates (98%). Higher vaccination coverage was protective against peak case rates (odds ratio 0.95, 95% CI 0.91–0.99) and against peak death rates (odds ratio 0.96, 95% CI 0.91–0.99). Vaccination coverage was vital to preventing infection and death from COVID-19 during the Delta wave. As new variants emerge, public health authorities should encourage the uptake of COVID-19 vaccination and boosters.

EID Atherstone CJ, Guagliardo SJ, Hawksworth A, O’Laughlin K, Wong K, Sloan ML, et al. COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020–2021. Emerg Infect Dis. 2023;29(9):1757-1764. https://doi.org/10.3201/eid2909.230142
AMA Atherstone CJ, Guagliardo SJ, Hawksworth A, et al. COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020–2021. Emerging Infectious Diseases. 2023;29(9):1757-1764. doi:10.3201/eid2909.230142.
APA Atherstone, C. J., Guagliardo, S. J., Hawksworth, A., O’Laughlin, K., Wong, K., Sloan, M. L....Bennett, S. D. (2023). COVID-19 Epidemiology during Delta Variant Dominance Period in 45 High-Income Countries, 2020–2021. Emerging Infectious Diseases, 29(9), 1757-1764. https://doi.org/10.3201/eid2909.230142.

Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020–2021 [PDF - 910 KB - 7 pages]
K. Newell et al.

Streptococcus pneumoniae can co-infect persons who have viral respiratory tract infections. However, research on S. pneumoniae infections that are temporally associated with SARS-CoV-2 infections is limited. We described the epidemiology and clinical course of patients who had invasive pneumococcal disease (IPD) and temporally associated SARS-CoV-2 infections in Alaska, USA, during January 1, 2020–December 23, 2021. Of 271 patients who had laboratory-confirmed IPD, 55 (20%) had a positive SARS-CoV-2 test result. We observed no major differences in age, race, sex, or underlying medical conditions among IPD patients with and without SARS-CoV-2. However, a larger proportion of IPD patients with SARS-CoV-2 died (16%, n = 9) than for those with IPD alone (4%, n = 9) (p<0.01). IPD patients with SARS-CoV-2 were also more likely to be experiencing homelessness (adjusted OR 3.5; 95% CI 1.7–7.5). Our study highlights the risk for dual infection and ongoing benefits of pneumococcal and COVID-19 vaccination, especially among vulnerable populations.

EID Newell K, Fischer M, Massey S, Orell L, Steinberg J, Tompkins M, et al. Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020–2021. Emerg Infect Dis. 2023;29(9):1765-1771. https://doi.org/10.3201/eid2909.230080
AMA Newell K, Fischer M, Massey S, et al. Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020–2021. Emerging Infectious Diseases. 2023;29(9):1765-1771. doi:10.3201/eid2909.230080.
APA Newell, K., Fischer, M., Massey, S., Orell, L., Steinberg, J., Tompkins, M....McLaughlin, J. (2023). Temporally Associated Invasive Pneumococcal Disease and SARS-CoV-2 Infection, Alaska, USA, 2020–2021. Emerging Infectious Diseases, 29(9), 1765-1771. https://doi.org/10.3201/eid2909.230080.

Validation of Claims-Based Algorithm for Lyme Disease, Massachusetts, USA [PDF - 746 KB - 8 pages]
N. M. Cocoros et al.

Compared with notifiable disease surveillance, claims-based algorithms estimate higher Lyme disease incidence, but their accuracy is unknown. We applied a previously developed Lyme disease algorithm (diagnosis code plus antimicrobial drug prescription dispensing within 30 days) to an administrative claims database in Massachusetts, USA, to identify a Lyme disease cohort during July 2000–June 2019. Clinicians reviewed and adjudicated medical charts from a cohort subset by using national surveillance case definitions. We calculated positive predictive values (PPVs). We identified 12,229 Lyme disease episodes in the claims database and reviewed and adjudicated 128 medical charts. The algorithmʼs PPV for confirmed, probable, or suspected cases was 93.8% (95% CI 88.1%–97.3%); the PPV was 66.4% (95% CI 57.5%–74.5%) for confirmed and probable cases only. In a high incidence setting, a claims-based algorithm identified cases with a high PPV, suggesting it can be used to assess Lyme disease burden and supplement traditional surveillance data.

EID Cocoros NM, Kluberg SA, Willis SJ, Forrow S, Gessner BD, Nutt CT, et al. Validation of Claims-Based Algorithm for Lyme Disease, Massachusetts, USA. Emerg Infect Dis. 2023;29(9):1772-1779. https://doi.org/10.3201/eid2909.221931
AMA Cocoros NM, Kluberg SA, Willis SJ, et al. Validation of Claims-Based Algorithm for Lyme Disease, Massachusetts, USA. Emerging Infectious Diseases. 2023;29(9):1772-1779. doi:10.3201/eid2909.221931.
APA Cocoros, N. M., Kluberg, S. A., Willis, S. J., Forrow, S., Gessner, B. D., Nutt, C. T....Stark, J. H. (2023). Validation of Claims-Based Algorithm for Lyme Disease, Massachusetts, USA. Emerging Infectious Diseases, 29(9), 1772-1779. https://doi.org/10.3201/eid2909.221931.

Genomic Characteristics of Emerging Intraerythrocytic Anaplasma capra and High Prevalence in Goats, China [PDF - 3.35 MB - 9 pages]
Z. Lin et al.

Anaplasma capra is an emerging tickborne human pathogen initially recognized in China in 2015; it has been reported in ticks and in a wide range of domestic and wild animals worldwide. We describe whole-genome sequences of 2 A. capra strains from metagenomic sequencing of purified erythrocytes from infected goats in China. The genome of A. capra was the smallest among members of the genus Anaplasma. The genomes of the 2 A. capra strains contained comparable G+C content and numbers of pseudogenes with intraerythrocytic Anaplasma species. The 2 A. capra strains had 54 unique genes. The prevalence of A. capra was high among goats in the 2 endemic areas. Phylogenetic analyses revealed that the A. capra strains detected in this study were basically classified into 2 subclusters with those previously detected in Asia. Our findings clarify details of the genomic characteristics of A. capra and shed light on its genetic diversity.

EID Lin Z, Du L, Zhang M, Han X, Wang B, Meng J, et al. Genomic Characteristics of Emerging Intraerythrocytic Anaplasma capra and High Prevalence in Goats, China. Emerg Infect Dis. 2023;29(9):1780-1788. https://doi.org/10.3201/eid2909.230131
AMA Lin Z, Du L, Zhang M, et al. Genomic Characteristics of Emerging Intraerythrocytic Anaplasma capra and High Prevalence in Goats, China. Emerging Infectious Diseases. 2023;29(9):1780-1788. doi:10.3201/eid2909.230131.
APA Lin, Z., Du, L., Zhang, M., Han, X., Wang, B., Meng, J....Cao, W. (2023). Genomic Characteristics of Emerging Intraerythrocytic Anaplasma capra and High Prevalence in Goats, China. Emerging Infectious Diseases, 29(9), 1780-1788. https://doi.org/10.3201/eid2909.230131.

Global Estimate of Human Brucellosis Incidence [PDF - 1.67 MB - 9 pages]
C. G. Laine et al.

Brucellosis is a major public health concern worldwide, especially for persons living in resource-limited settings. Historically, an evidence-based estimate of the global annual incidence of human cases has been elusive. We used international public health data to fill this information gap through application of risk metrics to worldwide and regional at-risk populations. We performed estimations using 3 statistical models (weighted average interpolation, bootstrap resampling, and Bayesian inference) and considered missing information. An evidence-based conservative estimate of the annual global incidence is 2.1 million, significantly higher than was previously assumed. Our models indicate Africa and Asia sustain most of the global risk and cases, although areas within the Americas and Europe remain of concern. This study reveals that disease risk and incidence are higher than previously suggested and lie mainly within resource-limited settings. Clarification of both misdiagnosis and underdiagnosis is required because those factors will amplify case estimates.

EID Laine CG, Johnson VE, Scott H, Arenas-Gamboa AM. Global Estimate of Human Brucellosis Incidence. Emerg Infect Dis. 2023;29(9):1789-1797. https://doi.org/10.3201/eid2909.230052
AMA Laine CG, Johnson VE, Scott H, et al. Global Estimate of Human Brucellosis Incidence. Emerging Infectious Diseases. 2023;29(9):1789-1797. doi:10.3201/eid2909.230052.
APA Laine, C. G., Johnson, V. E., Scott, H., & Arenas-Gamboa, A. M. (2023). Global Estimate of Human Brucellosis Incidence. Emerging Infectious Diseases, 29(9), 1789-1797. https://doi.org/10.3201/eid2909.230052.

Interspecies Transmission of Swine Influenza A Viruses and Human Seasonal Vaccine-Mediated Protection Investigated in Ferret Model [PDF - 4.14 MB - 10 pages]
P. M. van Diemen et al.

We investigated the infection dynamics of 2 influenza A(H1N1) virus isolates from the swine 1A.3.3.2 (pandemic 2009) and 1C (Eurasian, avian-like) lineages. The 1C-lineage virus, A/Pavia/65/2016, although phylogenetically related to swine-origin viruses, was isolated from a human clinical case. This strain infected ferrets, a human influenza model species, and could be transmitted by direct contact and, less efficiently, by airborne exposure. Infecting ferrets and pigs (the natural host) resulted in mild or inapparent clinical signs comparable to those observed with 1A.3.3.2-lineage swine-origin viruses. Both H1N1 viruses could infect pigs and were transmitted to cohoused ferrets. Ferrets vaccinated with a human 2016–17 seasonal influenza vaccine were protected against infection with the antigenically matched 1A pandemic 2009 virus but not against the swine-lineage 1C virus. Our results reaffirm the need for continuous influenza A virus surveillance in pigs and identification of candidate human vaccine viruses.

EID van Diemen PM, Byrne A, Ramsay AM, Watson S, Nunez A, v Moreno A, et al. Interspecies Transmission of Swine Influenza A Viruses and Human Seasonal Vaccine-Mediated Protection Investigated in Ferret Model. Emerg Infect Dis. 2023;29(9):1798-1807. https://doi.org/10.3201/eid2909.230066
AMA van Diemen PM, Byrne A, Ramsay AM, et al. Interspecies Transmission of Swine Influenza A Viruses and Human Seasonal Vaccine-Mediated Protection Investigated in Ferret Model. Emerging Infectious Diseases. 2023;29(9):1798-1807. doi:10.3201/eid2909.230066.
APA van Diemen, P. M., Byrne, A., Ramsay, A. M., Watson, S., Nunez, A., v Moreno, A....Everett, H. E. (2023). Interspecies Transmission of Swine Influenza A Viruses and Human Seasonal Vaccine-Mediated Protection Investigated in Ferret Model. Emerging Infectious Diseases, 29(9), 1798-1807. https://doi.org/10.3201/eid2909.230066.

Shifting Patterns of Influenza Circulation during the COVID-19 Pandemic, Senegal [PDF - 4.15 MB - 10 pages]
A. Lampros et al.

Historically low levels of seasonal influenza circulation were reported during the first years of the COVID-19 pandemic and were mainly attributed to implementation of nonpharmaceutical interventions. In tropical regions, influenza’s seasonality differs largely, and data on this topic are scarce. We analyzed data from Senegal’s sentinel syndromic surveillance network before and after the start of the COVID-19 pandemic to assess changes in influenza circulation. We found that influenza shows year-round circulation in Senegal and has 2 distinct epidemic peaks: during January–March and during the rainy season in August–October. During 2021–2022, the expected January–March influenza peak completely disappeared, corresponding to periods of active SARS-CoV-2 circulation. We noted an unexpected influenza epidemic peak during May–July 2022. The observed reciprocal circulation of SARS-CoV-2 and influenza suggests that factors such as viral interference might be at play and should be further investigated in tropical settings.

EID Lampros A, Talla C, Diarra M, Tall B, Sagne S, Diallo M, et al. Shifting Patterns of Influenza Circulation during the COVID-19 Pandemic, Senegal. Emerg Infect Dis. 2023;29(9):1808-1817. https://doi.org/10.3201/eid2909.230307
AMA Lampros A, Talla C, Diarra M, et al. Shifting Patterns of Influenza Circulation during the COVID-19 Pandemic, Senegal. Emerging Infectious Diseases. 2023;29(9):1808-1817. doi:10.3201/eid2909.230307.
APA Lampros, A., Talla, C., Diarra, M., Tall, B., Sagne, S., Diallo, M....Loucoubar, C. (2023). Shifting Patterns of Influenza Circulation during the COVID-19 Pandemic, Senegal. Emerging Infectious Diseases, 29(9), 1808-1817. https://doi.org/10.3201/eid2909.230307.

Molecular Characterization of Circulating Yellow Fever Viruses from Outbreak in Ghana, 2021–2022 [PDF - 1.70 MB - 9 pages]
J. Bonney et al.

Yellow fever virus, transmitted by infected Aedes spp. mosquitoes, causes an acute viral hemorrhagic disease. During October 2021–February 2022, a yellow fever outbreak in some communities in Ghana resulted in 70 confirmed cases with 35 deaths (case-fatality rate 50%). The outbreak started in a predominantly unvaccinated nomadic community in the Savannah region, from which 65% of the cases came. The molecular amplification methods we used for diagnosis produced full-length DNA sequences from 3 confirmed cases. Phylogenetic analysis characterized the 3 sequences within West Africa genotype II; strains shared a close homology with sequences from Cote d’Ivoire and Senegal. We deployed more sensitive advanced molecular diagnostic techniques, which enabled earlier detection, helped control spread, and improved case management. We urge increased efforts from health authorities to vaccinate vulnerable groups in difficult-to-access areas and to educate the population about potential risks for yellow fever infections.

EID Bonney J, Sanders T, Pratt D, Agbodzi B, Laryea D, Agyeman N, et al. Molecular Characterization of Circulating Yellow Fever Viruses from Outbreak in Ghana, 2021–2022. Emerg Infect Dis. 2023;29(9):1818-1826. https://doi.org/10.3201/eid2909.221671
AMA Bonney J, Sanders T, Pratt D, et al. Molecular Characterization of Circulating Yellow Fever Viruses from Outbreak in Ghana, 2021–2022. Emerging Infectious Diseases. 2023;29(9):1818-1826. doi:10.3201/eid2909.221671.
APA Bonney, J., Sanders, T., Pratt, D., Agbodzi, B., Laryea, D., Agyeman, N....Odoom, J. (2023). Molecular Characterization of Circulating Yellow Fever Viruses from Outbreak in Ghana, 2021–2022. Emerging Infectious Diseases, 29(9), 1818-1826. https://doi.org/10.3201/eid2909.221671.
Historical Review

Improvements and Persisting Challenges in COVID-19 Response Compared with 1918–19 Influenza Pandemic Response, New Zealand (Aotearoa) [PDF - 1.71 MB - 10 pages]
J. Summers et al.

Exploring the results of the COVID-19 response in New Zealand (Aotearoa) is warranted so that insights can inform future pandemic planning. We compared the COVID-19 response in New Zealand to that for the more severe 1918–19 influenza pandemic. Both pandemics were caused by respiratory viruses, but the 1918–19 pandemic was short, intense, and yielded a higher mortality rate. The government and societal responses to COVID-19 were vastly superior; responses had a clear strategic direction and included a highly effective elimination strategy, border restrictions, minimal community spread for 20 months, successful vaccination rollout, and strong central government support. Both pandemics involved a whole-of-government response, community mobilization, and use of public health and social measures. Nevertheless, lessons from 1918–19 on the necessity of action to prevent inequities among different social groups were not fully learned, as demonstrated by the COVID-19 response and its ongoing unequal health outcomes in New Zealand.

EID Summers J, Kvalsvig A, Barnard L, Bennett J, Harwood M, Wilson N, et al. Improvements and Persisting Challenges in COVID-19 Response Compared with 1918–19 Influenza Pandemic Response, New Zealand (Aotearoa). Emerg Infect Dis. 2023;29(9):1827-1836. https://doi.org/10.3201/eid2909.221265
AMA Summers J, Kvalsvig A, Barnard L, et al. Improvements and Persisting Challenges in COVID-19 Response Compared with 1918–19 Influenza Pandemic Response, New Zealand (Aotearoa). Emerging Infectious Diseases. 2023;29(9):1827-1836. doi:10.3201/eid2909.221265.
APA Summers, J., Kvalsvig, A., Barnard, L., Bennett, J., Harwood, M., Wilson, N....Baker, M. G. (2023). Improvements and Persisting Challenges in COVID-19 Response Compared with 1918–19 Influenza Pandemic Response, New Zealand (Aotearoa). Emerging Infectious Diseases, 29(9), 1827-1836. https://doi.org/10.3201/eid2909.221265.
Dispatches

Emergence of GII.4 Sydney[P16]-like Norovirus-Associated Gastroenteritis, China, 2020–2022 [PDF - 1.35 MB - 5 pages]
Y. Ao et al.

Newly evolved GII.4 Sydney[P16] norovirus with multiple residue mutations, already circulating in parts of China, became predominant and caused an abrupt increase in diagnosed norovirus cases among children with gastroenteritis in Shanghai during 2021–2022. Findings highlight the need for continuous long-term monitoring for GII.4 Sydney[P16] and emergent GII.4 norovirus variants.

EID Ao Y, Lu L, Xu J. Emergence of GII.4 Sydney[P16]-like Norovirus-Associated Gastroenteritis, China, 2020–2022. Emerg Infect Dis. 2023;29(9):1837-1841. https://doi.org/10.3201/eid2909.230383
AMA Ao Y, Lu L, Xu J. Emergence of GII.4 Sydney[P16]-like Norovirus-Associated Gastroenteritis, China, 2020–2022. Emerging Infectious Diseases. 2023;29(9):1837-1841. doi:10.3201/eid2909.230383.
APA Ao, Y., Lu, L., & Xu, J. (2023). Emergence of GII.4 Sydney[P16]-like Norovirus-Associated Gastroenteritis, China, 2020–2022. Emerging Infectious Diseases, 29(9), 1837-1841. https://doi.org/10.3201/eid2909.230383.

Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Wild Birds, Chile [PDF - 1.21 MB - 4 pages]
N. Ariyama et al.

In December 2022, highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b virus emerged in Chile. We detected H5N1 virus in 93 samples and obtained 9 whole-genome sequences of strains from wild birds. Phylogenetic analysis suggests multiple viral introductions into South America. Continued surveillance is needed to assess risks to humans and domestic poultry.

EID Ariyama N, Pardo-Roa C, Muñoz G, Aguayo C, Ávila C, Mathieu C, et al. Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Wild Birds, Chile. Emerg Infect Dis. 2023;29(9):1842-1845. https://doi.org/10.3201/eid2909.230067
AMA Ariyama N, Pardo-Roa C, Muñoz G, et al. Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Wild Birds, Chile. Emerging Infectious Diseases. 2023;29(9):1842-1845. doi:10.3201/eid2909.230067.
APA Ariyama, N., Pardo-Roa, C., Muñoz, G., Aguayo, C., Ávila, C., Mathieu, C....Neira, V. (2023). Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Virus in Wild Birds, Chile. Emerging Infectious Diseases, 29(9), 1842-1845. https://doi.org/10.3201/eid2909.230067.

Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022 [PDF - 803 KB - 4 pages]
S. Garba-Ouangole et al.

During 2016–2022, PCR testing confirmed 100 mpox cases among 302 suspected cases in the Central African Republic. The highest detection rates were from active lesions (40%) and scabs (36%); cycle thresholds were lower (≈18) than those for blood samples (≈33). Results were consistent for generic primer– and clade I primer–specific PCR tests.

EID Garba-Ouangole S, Bourner J, Mbrenga F, Gonofio E, Selekon B, Manirakiza A, et al. Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022. Emerg Infect Dis. 2023;29(9):1846-1849. https://doi.org/10.3201/eid2909.230514
AMA Garba-Ouangole S, Bourner J, Mbrenga F, et al. Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022. Emerging Infectious Diseases. 2023;29(9):1846-1849. doi:10.3201/eid2909.230514.
APA Garba-Ouangole, S., Bourner, J., Mbrenga, F., Gonofio, E., Selekon, B., Manirakiza, A....Nakouné, E. (2023). Laboratory Diagnosis of Mpox, Central African Republic, 2016–2022. Emerging Infectious Diseases, 29(9), 1846-1849. https://doi.org/10.3201/eid2909.230514.

Effects of School-Based Preventive Measures on COVID-19 Incidence, Hong Kong, 2022 [PDF - 1.99 MB - 5 pages]
T. K. Tsang et al.

We show that school closures reduced COVID-19 incidence rates in children by 31%–46% in Hong Kong in 2022. After school reopening accompanied by mask mandates, daily rapid testing, and vaccination requirements, school-reported cases correlated with community incidence rates. Safe school reopening is possible when appropriate preventive measures are used.

EID Tsang TK, Huang X, Fong M, Wang C, Lau E, Wu P, et al. Effects of School-Based Preventive Measures on COVID-19 Incidence, Hong Kong, 2022. Emerg Infect Dis. 2023;29(9):1850-1854. https://doi.org/10.3201/eid2909.221897
AMA Tsang TK, Huang X, Fong M, et al. Effects of School-Based Preventive Measures on COVID-19 Incidence, Hong Kong, 2022. Emerging Infectious Diseases. 2023;29(9):1850-1854. doi:10.3201/eid2909.221897.
APA Tsang, T. K., Huang, X., Fong, M., Wang, C., Lau, E., Wu, P....Cowling, B. J. (2023). Effects of School-Based Preventive Measures on COVID-19 Incidence, Hong Kong, 2022. Emerging Infectious Diseases, 29(9), 1850-1854. https://doi.org/10.3201/eid2909.221897.

Pharyngeal Co-Infections with Monkeypox Virus and Group A Streptococcus, United States, 2022 [PDF - 1.09 MB - 4 pages]
R. M. Kaiser et al.

We report 2 cases of pharyngeal monkeypox virus and group A Streptococcus co-infection in the United States. No rash was observed when pharyngitis symptoms began. One patient required intubation before mpox was diagnosed. Healthcare providers should be aware of oropharyngeal mpox manifestations and possible co-infections; early treatment might prevent serious complications.

EID Kaiser RM, Cash-Goldwasser S, Lehnertz N, Griffith J, Ruprecht A, Stanton J, et al. Pharyngeal Co-Infections with Monkeypox Virus and Group A Streptococcus, United States, 2022. Emerg Infect Dis. 2023;29(9):1855-1858. https://doi.org/10.3201/eid2909.230469
AMA Kaiser RM, Cash-Goldwasser S, Lehnertz N, et al. Pharyngeal Co-Infections with Monkeypox Virus and Group A Streptococcus, United States, 2022. Emerging Infectious Diseases. 2023;29(9):1855-1858. doi:10.3201/eid2909.230469.
APA Kaiser, R. M., Cash-Goldwasser, S., Lehnertz, N., Griffith, J., Ruprecht, A., Stanton, J....Lynfield, R. (2023). Pharyngeal Co-Infections with Monkeypox Virus and Group A Streptococcus, United States, 2022. Emerging Infectious Diseases, 29(9), 1855-1858. https://doi.org/10.3201/eid2909.230469.

Rapid Epidemic Expansion of Chikungunya Virus East/Central/South African Lineage, Paraguay [PDF - 1.39 MB - 5 pages]
M. Giovanetti et al.

The spread of Chikungunya virus is a major public health concern in the Americas. There were >120,000 cases and 51 deaths in 2023, of which 46 occurred in Paraguay. Using a suite of genomic, phylodynamic, and epidemiologic techniques, we characterized the ongoing large chikungunya epidemic in Paraguay.

EID Giovanetti M, Vazquez C, Lima M, Castro E, Rojas A, Gomez de la Fuente A, et al. Rapid Epidemic Expansion of Chikungunya Virus East/Central/South African Lineage, Paraguay. Emerg Infect Dis. 2023;29(9):1859-1863. https://doi.org/10.3201/eid2909.230523
AMA Giovanetti M, Vazquez C, Lima M, et al. Rapid Epidemic Expansion of Chikungunya Virus East/Central/South African Lineage, Paraguay. Emerging Infectious Diseases. 2023;29(9):1859-1863. doi:10.3201/eid2909.230523.
APA Giovanetti, M., Vazquez, C., Lima, M., Castro, E., Rojas, A., Gomez de la Fuente, A....Alcantara, L. (2023). Rapid Epidemic Expansion of Chikungunya Virus East/Central/South African Lineage, Paraguay. Emerging Infectious Diseases, 29(9), 1859-1863. https://doi.org/10.3201/eid2909.230523.

Population-Based Serologic Survey of Vibrio cholerae Antibody Titers before Cholera Outbreak, Haiti, 2022 [PDF - 1.01 MB - 4 pages]
C. H. Clutter et al.

A Vibrio cholerae O1 outbreak emerged in Haiti in October 2022 after years of cholera absence. In samples from a 2021 serosurvey, we found lower circulating antibodies against V. cholerae lipopolysaccharide in children <5 years of age and no vibriocidal antibodies, suggesting high susceptibility to cholera, especially among young children.

EID Clutter CH, Klarman MB, Cajusma Y, Cato ET, Abu Sayeed M, Brinkley L, et al. Population-Based Serologic Survey of Vibrio cholerae Antibody Titers before Cholera Outbreak, Haiti, 2022. Emerg Infect Dis. 2023;29(9):1864-1867. https://doi.org/10.3201/eid2909.230174
AMA Clutter CH, Klarman MB, Cajusma Y, et al. Population-Based Serologic Survey of Vibrio cholerae Antibody Titers before Cholera Outbreak, Haiti, 2022. Emerging Infectious Diseases. 2023;29(9):1864-1867. doi:10.3201/eid2909.230174.
APA Clutter, C. H., Klarman, M. B., Cajusma, Y., Cato, E. T., Abu Sayeed, M., Brinkley, L....Nelson, E. J. (2023). Population-Based Serologic Survey of Vibrio cholerae Antibody Titers before Cholera Outbreak, Haiti, 2022. Emerging Infectious Diseases, 29(9), 1864-1867. https://doi.org/10.3201/eid2909.230174.

Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022 [PDF - 1.28 MB - 4 pages]
R. Kinoshita et al.

A nationwide survey of SARS-CoV-2 antinucleocapsid seroprevalence among blood donors in Japan revealed that, as of November 2022, infection-induced seroprevalence of the population was 28.6% (95% CI 27.6%–29.6%). Seroprevalence studies might complement routine surveillance and ongoing monitoring efforts to provide a more complete real-time picture of COVID-19 burden.

EID Kinoshita R, Arashiro T, Kitamura N, Arai S, Takahashi K, Suzuki T, et al. Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022. Emerg Infect Dis. 2023;29(9):1868-1871. https://doi.org/10.3201/eid2909.230365
AMA Kinoshita R, Arashiro T, Kitamura N, et al. Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022. Emerging Infectious Diseases. 2023;29(9):1868-1871. doi:10.3201/eid2909.230365.
APA Kinoshita, R., Arashiro, T., Kitamura, N., Arai, S., Takahashi, K., Suzuki, T....Yoneoka, D. (2023). Infection-Induced SARS-CoV-2 Seroprevalence among Blood Donors, Japan, 2022. Emerging Infectious Diseases, 29(9), 1868-1871. https://doi.org/10.3201/eid2909.230365.

Prevalence of Asymptomatic Mpox among Men Who Have Sex with Men, Japan, January–March 2023 [PDF - 1.14 MB - 5 pages]
D. Mizushima et al.

We prospectively assessed asymptomatic monkeypox virus infections among men who have sex with men in Tokyo, Japan, during the initial phase of the mpox epidemic. Our findings suggest that asymptomatic infections were likely underestimated and were comparable in magnitude to symptomatic infections, highlighting the need to improve testing accessibility among high-risk populations.

EID Mizushima D, Shintani Y, Takano M, Shiojiri D, Ando N, Aoki T, et al. Prevalence of Asymptomatic Mpox among Men Who Have Sex with Men, Japan, January–March 2023. Emerg Infect Dis. 2023;29(9):1872-1876. https://doi.org/10.3201/eid2909.230541
AMA Mizushima D, Shintani Y, Takano M, et al. Prevalence of Asymptomatic Mpox among Men Who Have Sex with Men, Japan, January–March 2023. Emerging Infectious Diseases. 2023;29(9):1872-1876. doi:10.3201/eid2909.230541.
APA Mizushima, D., Shintani, Y., Takano, M., Shiojiri, D., Ando, N., Aoki, T....Oka, S. (2023). Prevalence of Asymptomatic Mpox among Men Who Have Sex with Men, Japan, January–March 2023. Emerging Infectious Diseases, 29(9), 1872-1876. https://doi.org/10.3201/eid2909.230541.

Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France [PDF - 1.72 MB - 5 pages]
A. B. Jousset et al.

Cefiderocol resistance is increasingly reported in New Delhi metallo-β-lactamase–producing Enterobacterales. Genomic and phenotypic analysis of Escherichia coli sequence type 361, a primary clone causing carbapenemase spread in France, revealed mutations leading to cefiderocol resistance. Continued genomic surveillance of carbapenem-resistant Enterobacterales could clarify prevalence of cefiderocol-resistant E. coli in Europe.

EID Jousset AB, Bouabdallah L, Birer A, Rosinski-Chupin I, Mariet J, Oueslati S, et al. Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France. Emerg Infect Dis. 2023;29(9):1877-1881. https://doi.org/10.3201/eid2909.230390
AMA Jousset AB, Bouabdallah L, Birer A, et al. Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France. Emerging Infectious Diseases. 2023;29(9):1877-1881. doi:10.3201/eid2909.230390.
APA Jousset, A. B., Bouabdallah, L., Birer, A., Rosinski-Chupin, I., Mariet, J., Oueslati, S....Dortet, L. (2023). Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France. Emerging Infectious Diseases, 29(9), 1877-1881. https://doi.org/10.3201/eid2909.230390.

Acute Chagas Disease Outbreak among Military Personnel, Colombia, 2021 [PDF - 598 KB - 4 pages]
H. Vergara et al.

We report an acute Chagas disease outbreak among soldiers in Colombia. Trypanosoma cruzi infection was confirmed through parasitology, serology, and molecular methods. Among 9 affected soldiers, 2 died; 7 were hospitalized and received benznidazole treatment, which produced favorable outcomes. Personnel patrolling rural areas in Colombia could be at increased risk for Chagas disease.

EID Vergara H, Gómez CH, Faccini-Martínez ÁA, Herrera A, López M, Camacho C, et al. Acute Chagas Disease Outbreak among Military Personnel, Colombia, 2021. Emerg Infect Dis. 2023;29(9):1882-1885. https://doi.org/10.3201/eid2909.230886
AMA Vergara H, Gómez CH, Faccini-Martínez ÁA, et al. Acute Chagas Disease Outbreak among Military Personnel, Colombia, 2021. Emerging Infectious Diseases. 2023;29(9):1882-1885. doi:10.3201/eid2909.230886.
APA Vergara, H., Gómez, C. H., Faccini-Martínez, Á. A., Herrera, A., López, M., Camacho, C....Ramírez, J. (2023). Acute Chagas Disease Outbreak among Military Personnel, Colombia, 2021. Emerging Infectious Diseases, 29(9), 1882-1885. https://doi.org/10.3201/eid2909.230886.

Lymphocytic Choriomeningitis Virus in Person Living with HIV, Connecticut, USA, 2021 [PDF - 621 KB - 4 pages]
J. Dyal et al.

Lymphocytic choriomeningitis virus is an underreported cause of miscarriage and neurologic disease. Surveillance remains challenging because of nonspecific symptomatology, inconsistent case reporting, and difficulties with diagnostic testing. We describe a case of acute lymphocytic choriomeningitis virus disease in a person living with HIV in Connecticut, USA, identified by using quantitative reverse transcription PCR.

EID Dyal J, Gandhi S, Cossaboom CM, Leach A, Patel K, Golden M, et al. Lymphocytic Choriomeningitis Virus in Person Living with HIV, Connecticut, USA, 2021. Emerg Infect Dis. 2023;29(9):1886-1889. https://doi.org/10.3201/eid2909.230087
AMA Dyal J, Gandhi S, Cossaboom CM, et al. Lymphocytic Choriomeningitis Virus in Person Living with HIV, Connecticut, USA, 2021. Emerging Infectious Diseases. 2023;29(9):1886-1889. doi:10.3201/eid2909.230087.
APA Dyal, J., Gandhi, S., Cossaboom, C. M., Leach, A., Patel, K., Golden, M....Shoemaker, T. (2023). Lymphocytic Choriomeningitis Virus in Person Living with HIV, Connecticut, USA, 2021. Emerging Infectious Diseases, 29(9), 1886-1889. https://doi.org/10.3201/eid2909.230087.

Rat Hepatitis E Virus in Norway Rats, Ontario, Canada, 2018–2021 [PDF - 1.26 MB - 5 pages]
S. J. Robinson et al.

We tested liver samples from 372 Norway rats (Rattus norvegicus) from southern Ontario, Canada, during 2018–2021 to investigate presence of hepatitis E virus infection. Overall, 21 (5.6%) rats tested positive for the virus. Sequence analysis demonstrated all infections to be rat hepatitis E virus (Rocahepevirus ratti genotype C1).

EID Robinson SJ, Borlang J, Himsworth CG, Pearl DL, Weese J, Dibernardo A, et al. Rat Hepatitis E Virus in Norway Rats, Ontario, Canada, 2018–2021. Emerg Infect Dis. 2023;29(9):1890-1894. https://doi.org/10.3201/eid2909.230517
AMA Robinson SJ, Borlang J, Himsworth CG, et al. Rat Hepatitis E Virus in Norway Rats, Ontario, Canada, 2018–2021. Emerging Infectious Diseases. 2023;29(9):1890-1894. doi:10.3201/eid2909.230517.
APA Robinson, S. J., Borlang, J., Himsworth, C. G., Pearl, D. L., Weese, J., Dibernardo, A....Jardine, C. M. (2023). Rat Hepatitis E Virus in Norway Rats, Ontario, Canada, 2018–2021. Emerging Infectious Diseases, 29(9), 1890-1894. https://doi.org/10.3201/eid2909.230517.

Reoccurring Escherichia coli O157:H7 Strain Linked to Leafy Greens–Associated Outbreaks, 2016–2019 [PDF - 1.74 MB - 5 pages]
J. C. Chen et al.

Genomic characterization of an Escherichia coli O157:H7 strain linked to leafy greens–associated outbreaks dates its emergence to late 2015. One clade has notable accessory genomic content and a previously described mutation putatively associated with increased arsenic tolerance. This strain is a reoccurring, emerging, or persistent strain causing illness over an extended period.

EID Chen JC, Patel K, Smith PA, Vidyaprakash E, Snyder C, Tagg KA, et al. Reoccurring Escherichia coli O157:H7 Strain Linked to Leafy Greens–Associated Outbreaks, 2016–2019. Emerg Infect Dis. 2023;29(9):1895-1899. https://doi.org/10.3201/eid2909.230069
AMA Chen JC, Patel K, Smith PA, et al. Reoccurring Escherichia coli O157:H7 Strain Linked to Leafy Greens–Associated Outbreaks, 2016–2019. Emerging Infectious Diseases. 2023;29(9):1895-1899. doi:10.3201/eid2909.230069.
APA Chen, J. C., Patel, K., Smith, P. A., Vidyaprakash, E., Snyder, C., Tagg, K. A....Carleton, H. A. (2023). Reoccurring Escherichia coli O157:H7 Strain Linked to Leafy Greens–Associated Outbreaks, 2016–2019. Emerging Infectious Diseases, 29(9), 1895-1899. https://doi.org/10.3201/eid2909.230069.

Human Neural Larva Migrans Caused by Ophidascaris robertsi Ascarid [PDF - 1.21 MB - 4 pages]
M. Hossain et al.

We describe a case in Australia of human neural larva migrans caused by the ascarid Ophidascaris robertsi, for which Australian carpet pythons are definitive hosts. We made the diagnosis after a live nematode was removed from the brain of a 64-year-old woman who was immunosuppressed for a hypereosinophilic syndrome diagnosed 12 months earlier.

EID Hossain M, Kennedy KJ, Wilson HL, Spratt D, Koehler A, Gasser RB, et al. Human Neural Larva Migrans Caused by Ophidascaris robertsi Ascarid. Emerg Infect Dis. 2023;29(9):1900-1903. https://doi.org/10.3201/eid2909.230351
AMA Hossain M, Kennedy KJ, Wilson HL, et al. Human Neural Larva Migrans Caused by Ophidascaris robertsi Ascarid. Emerging Infectious Diseases. 2023;29(9):1900-1903. doi:10.3201/eid2909.230351.
APA Hossain, M., Kennedy, K. J., Wilson, H. L., Spratt, D., Koehler, A., Gasser, R. B....Senanayake, S. N. (2023). Human Neural Larva Migrans Caused by Ophidascaris robertsi Ascarid. Emerging Infectious Diseases, 29(9), 1900-1903. https://doi.org/10.3201/eid2909.230351.

Anaplasma bovis–Like Infections in Humans, United States, 2015–2017 [PDF - 542 KB - 4 pages]
S. E. Karpathy et al.

We detected the DNA of an Anaplasma bovis–like bacterium in blood specimens from 4 patients from the United States with suspected tickborne illnesses. Initial molecular characterization of this novel agent reveals identity to A. bovis–like bacteria detected in Dermacentor variabilis ticks collected from multiple US states.

EID Karpathy SE, Kingry L, Pritt BS, Berry JC, Chilton NB, Dergousoff SJ, et al. Anaplasma bovis–Like Infections in Humans, United States, 2015–2017. Emerg Infect Dis. 2023;29(9):1904-1907. https://doi.org/10.3201/eid2909.230559
AMA Karpathy SE, Kingry L, Pritt BS, et al. Anaplasma bovis–Like Infections in Humans, United States, 2015–2017. Emerging Infectious Diseases. 2023;29(9):1904-1907. doi:10.3201/eid2909.230559.
APA Karpathy, S. E., Kingry, L., Pritt, B. S., Berry, J. C., Chilton, N. B., Dergousoff, S. J....Paddock, C. D. (2023). Anaplasma bovis–Like Infections in Humans, United States, 2015–2017. Emerging Infectious Diseases, 29(9), 1904-1907. https://doi.org/10.3201/eid2909.230559.

Novel Echarate Virus Variant Isolated from Patient with Febrile Illness, Chanchamayo, Peru [PDF - 1.65 MB - 5 pages]
G. Troncos et al.

A new phlebovirus variant was isolated from an acute febrile patient in Chanchamayo, Peru. Genome characterization and p-distance analyses based on complete open reading frames revealed that the virus is probably a natural reassortant of the Echarate virus (large and small segments) with a yet-unidentified phlebovirus (M segment).

EID Troncos G, Popuche D, Adhikari BN, Long KA, Ríos J, Valerio M, et al. Novel Echarate Virus Variant Isolated from Patient with Febrile Illness, Chanchamayo, Peru. Emerg Infect Dis. 2023;29(9):1908-1912. https://doi.org/10.3201/eid2909.230374
AMA Troncos G, Popuche D, Adhikari BN, et al. Novel Echarate Virus Variant Isolated from Patient with Febrile Illness, Chanchamayo, Peru. Emerging Infectious Diseases. 2023;29(9):1908-1912. doi:10.3201/eid2909.230374.
APA Troncos, G., Popuche, D., Adhikari, B. N., Long, K. A., Ríos, J., Valerio, M....Cruz, C. D. (2023). Novel Echarate Virus Variant Isolated from Patient with Febrile Illness, Chanchamayo, Peru. Emerging Infectious Diseases, 29(9), 1908-1912. https://doi.org/10.3201/eid2909.230374.

High Prevalence of Candida auris Colonization during Protracted Neonatal Unit Outbreak, South Africa [PDF - 1.28 MB - 4 pages]
L. Shuping et al.

One third of patients were colonized by Candida auris during a point-prevalence survey in a neonatal unit during an outbreak in South Africa. The sensitivity of a direct PCR for rapid colonization detection was 44% compared with culture. The infection incidence rate decreased by 85% after the survey and implementation of isolation/cohorting.

EID Shuping L, Maphanga TG, Naicker SD, Mpembe R, Ngoma N, Velaphi S, et al. High Prevalence of Candida auris Colonization during Protracted Neonatal Unit Outbreak, South Africa. Emerg Infect Dis. 2023;29(9):1913-1916. https://doi.org/10.3201/eid2909.230393
AMA Shuping L, Maphanga TG, Naicker SD, et al. High Prevalence of Candida auris Colonization during Protracted Neonatal Unit Outbreak, South Africa. Emerging Infectious Diseases. 2023;29(9):1913-1916. doi:10.3201/eid2909.230393.
APA Shuping, L., Maphanga, T. G., Naicker, S. D., Mpembe, R., Ngoma, N., Velaphi, S....Govender, N. P. (2023). High Prevalence of Candida auris Colonization during Protracted Neonatal Unit Outbreak, South Africa. Emerging Infectious Diseases, 29(9), 1913-1916. https://doi.org/10.3201/eid2909.230393.

Fatal Necrotizing Enterocolitis in Neonate Caused by Cronobacter sakazakii Sequence Type 64 Strain of CRISPR Sublineage b [PDF - 1.81 MB - 4 pages]
H. Zeng et al.

We report fatal neonatal necrotizing enterocolitis in China caused by Cronobacter sakazakii capsular profile K1:CA1, sequence type 64, and CRISPR type 197. Phylodynamic analyses indicated that the strain originated from the ancient, widespread, and antimicrobial drug–sensitive CRISPR sublineage b. Enhanced surveillance and pathogenesis research on this organism are required.

EID Zeng H, Li C, Zhang J, Liang B, Mei H, Wu Q. Fatal Necrotizing Enterocolitis in Neonate Caused by Cronobacter sakazakii Sequence Type 64 Strain of CRISPR Sublineage b. Emerg Infect Dis. 2023;29(9):1917-1920. https://doi.org/10.3201/eid2909.230537
AMA Zeng H, Li C, Zhang J, et al. Fatal Necrotizing Enterocolitis in Neonate Caused by Cronobacter sakazakii Sequence Type 64 Strain of CRISPR Sublineage b. Emerging Infectious Diseases. 2023;29(9):1917-1920. doi:10.3201/eid2909.230537.
APA Zeng, H., Li, C., Zhang, J., Liang, B., Mei, H., & Wu, Q. (2023). Fatal Necrotizing Enterocolitis in Neonate Caused by Cronobacter sakazakii Sequence Type 64 Strain of CRISPR Sublineage b. Emerging Infectious Diseases, 29(9), 1917-1920. https://doi.org/10.3201/eid2909.230537.

Home-Based Testing and COVID-19 Isolation Recommendations, United States [PDF - 850 KB - 4 pages]
P. K. Moonan et al.

Using a nationally representative panel survey, we examined isolation behaviors among persons in the United States who had positive SARS-CoV-2 test results during January 2021–March 2022. Compared with persons who received provider-administered results, persons with home-based results had 29% (95% CI 5%–47%) lower odds of following isolation recommendations.

EID Moonan PK, Smith JP, Borah BF, Vohra D, Matulewicz HH, DeLuca N, et al. Home-Based Testing and COVID-19 Isolation Recommendations, United States. Emerg Infect Dis. 2023;29(9):1921-1924. https://doi.org/10.3201/eid2909.230494
AMA Moonan PK, Smith JP, Borah BF, et al. Home-Based Testing and COVID-19 Isolation Recommendations, United States. Emerging Infectious Diseases. 2023;29(9):1921-1924. doi:10.3201/eid2909.230494.
APA Moonan, P. K., Smith, J. P., Borah, B. F., Vohra, D., Matulewicz, H. H., DeLuca, N....Oeltmann, J. E. (2023). Home-Based Testing and COVID-19 Isolation Recommendations, United States. Emerging Infectious Diseases, 29(9), 1921-1924. https://doi.org/10.3201/eid2909.230494.

Evaluating SARS-CoV-2 Saliva and Dried Blood Spot Surveillance Strategies in a Congregate Population [PDF - 669 KB - 4 pages]
L. R. Andronescu et al.

The optimal approach to COVID-19 surveillance in congregate populations remains unclear. Our study at the US Naval Academy in Annapolis, Maryland, USA, assessed the concordance of antibody prevalence in longitudinally collected dried blood spots and saliva in a setting of frequent PCR-based testing. Our findings highlight the utility of salivary-based surveillance.

EID Andronescu LR, Richard SA, Laing ED, Pisanic N, Coggins SA, Rivera M, et al. Evaluating SARS-CoV-2 Saliva and Dried Blood Spot Surveillance Strategies in a Congregate Population. Emerg Infect Dis. 2023;29(9):1925-1928. https://doi.org/10.3201/eid2909.230417
AMA Andronescu LR, Richard SA, Laing ED, et al. Evaluating SARS-CoV-2 Saliva and Dried Blood Spot Surveillance Strategies in a Congregate Population. Emerging Infectious Diseases. 2023;29(9):1925-1928. doi:10.3201/eid2909.230417.
APA Andronescu, L. R., Richard, S. A., Laing, E. D., Pisanic, N., Coggins, S. A., Rivera, M....Simons, M. P. (2023). Evaluating SARS-CoV-2 Saliva and Dried Blood Spot Surveillance Strategies in a Congregate Population. Emerging Infectious Diseases, 29(9), 1925-1928. https://doi.org/10.3201/eid2909.230417.

Seroprevalence of Vibrio cholerae in Adults, Haiti, 2017 [PDF - 445 KB - 4 pages]
W. R. Matias et al.

In Haiti in 2017, the prevalence of serum vibriocidal antibody titers against Vibrio cholerae serogroup O1 among adults was 12.4% in Cerca-la-Source and 9.54% in Mirebalais, suggesting a high recent prevalence of infection. Improved surveillance programs to monitor cholera and guide public health interventions in Haiti are necessary.

EID Matias WR, Guillaume Y, Augustin G, Vissieres K, Ternier R, Charles RC, et al. Seroprevalence of Vibrio cholerae in Adults, Haiti, 2017. Emerg Infect Dis. 2023;29(9):1929-1932. https://doi.org/10.3201/eid2909.230401
AMA Matias WR, Guillaume Y, Augustin G, et al. Seroprevalence of Vibrio cholerae in Adults, Haiti, 2017. Emerging Infectious Diseases. 2023;29(9):1929-1932. doi:10.3201/eid2909.230401.
APA Matias, W. R., Guillaume, Y., Augustin, G., Vissieres, K., Ternier, R., Charles, R. C....Ivers, L. C. (2023). Seroprevalence of Vibrio cholerae in Adults, Haiti, 2017. Emerging Infectious Diseases, 29(9), 1929-1932. https://doi.org/10.3201/eid2909.230401.
Photo Quizzes

Photo Quiz [PDF - 1.68 MB - 4 pages]
M. Martini
EID Martini M. WHO Doctor and Hero of SARS in 2003. Emerg Infect Dis. 2023;29(9):1933-1936. https://doi.org/10.3201/eid2909.212412
AMA Martini M. WHO Doctor and Hero of SARS in 2003. Emerging Infectious Diseases. 2023;29(9):1933-1936. doi:10.3201/eid2909.212412.
APA Martini, M. (2023). WHO Doctor and Hero of SARS in 2003. Emerging Infectious Diseases, 29(9), 1933-1936. https://doi.org/10.3201/eid2909.212412.
Research Letters

Group A Streptococcus Meningitis in Adults, Denmark [PDF - 562 KB - 3 pages]
H. Nielsen et al.

We report a 21-fold increase in group A Streptococcus meningitis in adults in Denmark during October 13, 2022–April 12, 2023, concurrent with an outbreak of invasive streptococcal disease. We describe clinical characteristics of the outbreak cases and prognosis for patients in comparison to those for previous sporadic cases.

EID Nielsen H, Storgaard M, Helweg-Larsen J, Larsen L, Jepsen M, Hansen BR, et al. Group A Streptococcus Meningitis in Adults, Denmark. Emerg Infect Dis. 2023;29(9):1937-1939. https://doi.org/10.3201/eid2909.230627
AMA Nielsen H, Storgaard M, Helweg-Larsen J, et al. Group A Streptococcus Meningitis in Adults, Denmark. Emerging Infectious Diseases. 2023;29(9):1937-1939. doi:10.3201/eid2909.230627.
APA Nielsen, H., Storgaard, M., Helweg-Larsen, J., Larsen, L., Jepsen, M., Hansen, B. R....Bodilsen, J. (2023). Group A Streptococcus Meningitis in Adults, Denmark. Emerging Infectious Diseases, 29(9), 1937-1939. https://doi.org/10.3201/eid2909.230627.

Patient Characteristics During Early Transmission of SARS-CoV-2, Palau, January 13–February 24, 2022 [PDF - 229 KB - 3 pages]
B. Eilers et al.

Palau had no reported evidence of COVID-19 community spread until January 2022. We chart reviewed hospitalized patients who had a positive SARS-CoV-2 test result during early community transmission. Booster vaccinations and early outpatient treatment decreased hospitalizations. Inadequate hospital infection control practices contributed to iatrogenic COVID-19 and preventable deaths.

EID Eilers B, Adelbai-Fraser MD, Collado JR, Van Dyke M, Firestone M, Guinn AS, et al. Patient Characteristics During Early Transmission of SARS-CoV-2, Palau, January 13–February 24, 2022. Emerg Infect Dis. 2023;29(9):1939-1941. https://doi.org/10.3201/eid2909.230182
AMA Eilers B, Adelbai-Fraser MD, Collado JR, et al. Patient Characteristics During Early Transmission of SARS-CoV-2, Palau, January 13–February 24, 2022. Emerging Infectious Diseases. 2023;29(9):1939-1941. doi:10.3201/eid2909.230182.
APA Eilers, B., Adelbai-Fraser, M. D., Collado, J. R., Van Dyke, M., Firestone, M., Guinn, A. S....Hancock, W. (2023). Patient Characteristics During Early Transmission of SARS-CoV-2, Palau, January 13–February 24, 2022. Emerging Infectious Diseases, 29(9), 1939-1941. https://doi.org/10.3201/eid2909.230182.

Partial Genome Characterization of Novel Parapoxvirus in Horse, Finland [PDF - 805 KB - 4 pages]
J. Virtanen et al.

We report a sequencing protocol and 121-kb poxvirus sequence from a clinical sample from a horse in Finland with dermatitis. Based on phylogenetic analyses, the virus is a novel parapoxvirus associated with a recent epidemic; previous data suggest zoonotic potential. Increased awareness of this virus and specific diagnostic protocols are needed.

EID Virtanen J, Hautaniemi M, Dutra L, Plyusnin I, Hautala K, Smura T, et al. Partial Genome Characterization of Novel Parapoxvirus in Horse, Finland. Emerg Infect Dis. 2023;29(9):1941-1944. https://doi.org/10.3201/eid2909.230049
AMA Virtanen J, Hautaniemi M, Dutra L, et al. Partial Genome Characterization of Novel Parapoxvirus in Horse, Finland. Emerging Infectious Diseases. 2023;29(9):1941-1944. doi:10.3201/eid2909.230049.
APA Virtanen, J., Hautaniemi, M., Dutra, L., Plyusnin, I., Hautala, K., Smura, T....Kinnunen, P. M. (2023). Partial Genome Characterization of Novel Parapoxvirus in Horse, Finland. Emerging Infectious Diseases, 29(9), 1941-1944. https://doi.org/10.3201/eid2909.230049.

Rickettsial Disease Outbreak, Mexico, 2022 [PDF - 1.12 MB - 4 pages]
R. J. Estrada-Mendizabal et al.

Beginning in 2022, Nuevo Leon, Mexico, experienced an outbreak of rickettsioses that is still ongoing despite multidisciplinary control efforts. A total of 57 cases have been confirmed, particularly affecting children. We report a high mortality rate among hospitalized persons in Nuevo Leon. Continuing efforts are required to control the outbreak.

EID Estrada-Mendizabal RJ, Tamez-Rivera O, Vela E, Blanco-Murillo P, Alanis-Garza C, Flores-Gouyonnet J, et al. Rickettsial Disease Outbreak, Mexico, 2022. Emerg Infect Dis. 2023;29(9):1944-1947. https://doi.org/10.3201/eid2909.230344
AMA Estrada-Mendizabal RJ, Tamez-Rivera O, Vela E, et al. Rickettsial Disease Outbreak, Mexico, 2022. Emerging Infectious Diseases. 2023;29(9):1944-1947. doi:10.3201/eid2909.230344.
APA Estrada-Mendizabal, R. J., Tamez-Rivera, O., Vela, E., Blanco-Murillo, P., Alanis-Garza, C., Flores-Gouyonnet, J....Escamilla, A. (2023). Rickettsial Disease Outbreak, Mexico, 2022. Emerging Infectious Diseases, 29(9), 1944-1947. https://doi.org/10.3201/eid2909.230344.
About the Cover

B for Beethoven [PDF - 1.67 MB - 2 pages]
T. Chorba
EID Chorba T. B for Beethoven. Emerg Infect Dis. 2023;29(9):1948-1949. https://doi.org/10.3201/eid2909.ac2909
AMA Chorba T. B for Beethoven. Emerging Infectious Diseases. 2023;29(9):1948-1949. doi:10.3201/eid2909.ac2909.
APA Chorba, T. (2023). B for Beethoven. Emerging Infectious Diseases, 29(9), 1948-1949. https://doi.org/10.3201/eid2909.ac2909.
Page created: August 20, 2023
Page updated: September 07, 2023
Page reviewed: September 07, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
edit_01 ScholarOne Submission Portal
Issue Select
GO
GO

Spotlight Topics

 

 

Get Email Updates

To receive email updates about this page, enter your email address:

file_external